Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

NCT03703375 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, T-Cell

Interventions

DRUG: Azacitidine
DRUG: Romidepsin
DRUG: Gemcitabine

Sponsor

Celgene